AKT1 and non-small cell lung carcinoma: In conclusion, our study offers robust pharmacological evidence that BA, a principal bioactive constituent of PNO, inhibits NSCLC progression by targeting the PI3K/AKT signaling pathway and downregulating ABCB1 expression.